Gastro-enteropancreatic Neuroendocrine Tumor Clinical Trial
Official title:
Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor
Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04614766 -
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03220217 -
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
|
Phase 2 | |
| Active, not recruiting |
NCT05050942 -
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
|
Phase 3 | |
| Recruiting |
NCT03475953 -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06253897 -
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
|
||
| Recruiting |
NCT03863106 -
The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
|
||
| Active, not recruiting |
NCT03972488 -
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
|
Phase 3 | |
| Terminated |
NCT03042780 -
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
|
Phase 2 | |
| Active, not recruiting |
NCT03600233 -
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT01423734 -
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
|